Peregrine powers up relationship with Paul Scherrer Institut

Radiopharmaceutical developer Peregrine Pharmaceuticals has extended its radiolabeling research and development agreement with Paul Scherrer Institut (PSI) of Villigen, Switzerland. The Tustin, CA-based firm has extended its contract with PSI to include research, development, and pre-clinical testing of Tumor Necrosis Therapy (TNT)-based PET imaging agents. Peregrine has been collaborating with PSI to scale-up the radiolabeling processes for its Cotara and Oncolym monoclonal antibody anti-cancer drugs.

By AuntMinnie.com staff writers
March 13, 2001

Copyright © 2001 AuntMinnie.com

Page 1 of 3617
Next Page